About the Study
The POTEN-C trial combines SAbR with SpaceOAR, a gel that increases the space between the prostate and rectum during radiation therapy. The idea is that this extra space will reduce the risk of sexual side effects after treatment even more than the current generation of SAbR techniques.
UT Southwestern was an early adopter of SpaceOAR gel, demonstrating its ability to reduce radiation effects on the lining of the rectum during SAbR and serving as a lead training site for its use in Texas.
SAbR, also known as SBRT, involves applying a precisely targeted dose of radiation directly to the tumor and sparing nearby healthy tissue. The treatment takes place over one to five outpatient visits to an academic medical center such as UT Southwestern.
In terms of sexual health, men who chose SAbR in our previous trials achieved favorable sexual function outcomes – including higher potency preservation – in the months and years that followed compared to historical data from other forms of radiotherapy and traditional surgery, especially when the surgery was not nerve sparing.
The POTEN-C clinical trial seeks to refine the SAbR treatment even further, preserving more patients’ sexual function, satisfaction, and overall quality of life. With the increased flexibility of treatment planning provided by SpaceOAR gel displacing the rectum, we hypothesize in this study that dedicated application of SAbR to spare nerves and vessels involved in sexual function will further improve potency rates after treatment.
Men who are newly diagnosed with prostate cancer or who have been on active surveillance might be candidates for the POTEN-C trial. A total of 120 participants nationwide will be recruited for this trial. Learn more about the POTEN-C trial.
Patients should always speak with their doctors about clinical trial opportunities.